4Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classification on 431 unselected patients from a single institute . Blood, 2001,98:2935～2941.
3Steensma DP,Tefferi A.The myelodysplastic syndrome (s):a perspective and review highlighting current controversies[J].Leuk Res,2003,27(2):95-120.
4Killick SB,Mufti G,Cavenagh JD,et al.A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ′low-risk′ myelodysplasia[J].Br J Haematol,2003,120(4):679-684.
5Shimamoto T,Ohyashiki K.Immunosuppressive treatments for myelodysplastic syndromes[J].Leuk Lymphoma,2003,44(4):593-604.
6Drabick JJ,Davis BJ,Byrd JC.Concurrent pernicious anemia and myelodysplastic syndrome[J].Ann Hematol,2001,80(4):243-245.
7Novaretti MC,Sopelete CR,Velloso ER,et al.Immunohematological findings in myelodysplastic syndrome[J].Acta Haematol,2001,105(1):1-6.
8Vardiman JW,Harris NL,Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms[J].Blood,2002,100(7):2292-2302.
9Germing U,Gattermann N,Strupp C,et al.Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes:a retrospective analysis of 1600 patients[J].Leuk Res,2000,24(12):983-992.
10Nsslinger T,Reisner R,Koller E,et al.Myelodys plastic syndromes,from French-Americam-British to World Health Organization:comprison of classification on 431 unselected patients from a single institute[J].Blood,2001,98(10):2935-2941.
